Ulceration of the small and large bowel mucosa in resection specimens of cystic fibrosis patients with fibrosing colonopathy

International Journal of Toxicology

Volumn 17, Issue 1, 1998, Pages 77-99

  Lannon, C L ^a   Hinchliffe, S A ^b   Pope, J D ^c   Ball, L M ^a   Van Velzen, D ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cystic fibrosis; Enteric coating; Eudragit; Fibrosing colonopathy

Indexed keywords

ACRYLIC ACID ETHYL ESTER; DODECYL SULFATE SODIUM; EUDRAGIT; METHACRYLIC ACID DERIVATIVE; PANCREAS ENZYME; POLYSORBATE 80; TRIACYLGLYCEROL LIPASE;

ARTICLE; ASCENDING COLON; CECUM; CLINICAL ARTICLE; COLON DISEASE; CONTROLLED STUDY; CYSTIC FIBROSIS; ENTERIC COATED TABLET; FIBROSING COLONOPATHY; HUMAN; HUMAN TISSUE; ILEUM; INTESTINE MUCOSA; INTESTINE ULCER; THREE DIMENSIONAL IMAGING;

EID: 0031908218     PISSN: 10915818     EISSN: None     Source Type: Journal    
DOI: 10.1080/109158198226765     Document Type: Article

References (33)

1. American Pharmaceutical Association/The Pharmaceutical Society of Great Britain. 1986. Handbook of Pharmaceutical Excipients. Washington, DC: APA/PSGB.
2. Bowler, I. M., Wolfe, S. P., Owens, H. M., Sheldon, T. A., Littlewood, J. M., and Walters, M. P. 1993. A double blind lipase for lipase comparison of a high lipase and standard pancreatic enzyme preparation in cystic fibrosis. Arch. Dis. Child. 68:277-230.
3. Campbell, C. A., Forrest, J., and Musgrove, C. 1994. High strength pancreatic enzyme supplements and large bowel stricture in cystic fibrosis. Lancet 343:109-110.
4. Croft, N. M., Marshall, T. G., and Ferguson, A. 1995. Gut inflammation in children with cystic fibrosis on high-dose enzyme supplements. Lancet 346:1265-1266.
5. Dean, M., White, M. B., Amos, J., Gerrard, G., Stewart, C., Khaw, K., and Leppert, M. 1990. Multiple mutations in highly conserved residues are found in mildly affected cystic fibrosis patients. Cell 61:863-870.
6. De Bethizy, J. D., Udinsky, J. R., Scribner, H. E., and Frederick, C. B. 1987. The disposition and metabolism of acrylic acid and ethyl acrylate in male Sprague Dawley rats. Fundam. Appl. Toxicol. 8:549-561.
7. Dodge, J. A. 1996. The aetiology of fibrosing colonopathy. Postgrad. Med. J. 72(suppl. 2):52-55.
8. Gaskin, K., Gurwitz, D., Durie, P., Corey, M., Levison, H., and Forstner, G. 1982. Improved respiratory prognosis in patients with cystic fibrosis and normal fat absorption. J. Pediatr. 100:857-862.
9. Ghanayem, B. I., Maronpot, R. R., and Matthews, H. B. 1986. Ethyl-acrylate induced gastric toxicity III. Toxicol. Appl. Pharmacol. 83:576-583.
10. Gow, R., Bradbear, R., Francis, P., and Shepherd, R. 1981. Comparative study of varying regimes to improve steatorrhoea and creatorrhoea in cystic fibrosis: Effectiveness of an enteric coated preparation with and without antacids and cimetidine. Lancet 2:1071-1074.
11. Graham, D. Y. 1977. Enzyme replacement therapy of exocrine pancreatic insufficiency in man: relation between in vitro enzyme activities and in vivo potency in commercial pancreatic extracts. N. Engl. J. Med. 296:1314-1317.
12. Huang, N. N., Schidlow, D. V., Szatrowski, H., Palmer, J., Laraya-Cuasay, L. R., Yeung, W., Hardy, K., Quitell, L., and Fiel, S. 1987. Clinical features, survival rate and prognostic factors in young adults with cystic fibrosis. Am. J. Med. 82:871-879.
13. Kapadia, C. 1996. Fibrosing colonopathy in cystic fibrosis: Results of a case control study. Gastroenterology 111:260-261.
14. Kerem, B., Zielenski, J., Markiewicz, D., Bozon, D., Gazit, E., Yahov, J., Kennedy, D., Riordan, J. R., Collins, F. S., Rommens, J. M., and Tsui, L. 1990. Identification of mutations in regions corresponding to the two putative nucleotide (ATP)-binding folds of the cystic fibrosis gene. Proc. Natl. Acad. Sci. USA 87:8447-8451.
15. Littlewood, J. M., and Hind, C. R. K., eds. 1996. Fibrosing Colonopathy in Children with Cystic Fibrosis. PMJ 72(suppl. 2). Cambridge: BMJ Publishing Group, Cambridge University Press.
16. Meyer, J. H., Elashoff, J., Porter-Fink, V., Dressman, J., and Amidon, G. L. 1988. Human postprandial gastric emptying of 1-3 millimetre spheres. Gastroenterology 94:1315-1325.
17. Morrison, G., Morrison, J., Redmon, A., Byers, C., McCracken, K., and Dodge, J. 1991. Pancreatic enzyme supplementation in cystic fibrosis. Lancet 338:1596-1597.
18. Oades, P. J., Bush, A., Ong, P. S., and Brereton, R. J. 1994. High strength pancreatic enzyme supplements and large bowel stricture in cystic fibrosis. Lancet 343:109.
19. Pawel, B. R., de Chadarevian, J. P., and Franco, M. E. 1997. The pathology of fibrosing colonopathy of cystic fibrosis: A study of 12 cases and review of the literature. Hum. Pathol. 28:395-399.
20. Pettei, M. J., Leonidas, J. C., Levine, J. J., and Gorvoy, J. D. 1994. Pancolonic disease in cystic fibrosis and high dose pancreatic enzyme therapy. J. Pediatr. 125:587-589.
21. Rohm, GmbH. 1993. Toxicology of Eudragit L30D-55 and Eudragit L100D-55 Pharma Polymers. Darmstadt, Germany: Rohm GmbH.
22. Schwarzenberg, S. J., Wielinski, C. L., Shamieh, I., Carpenter, B. L. M., Jessurun, J., Weisdorf, S. A., Warwick, W. J., and Sharp, H. L. 1995. Cystic fibrosis-associated colitis and fibrosing colonopathy. J. Pediatr. 127:565-570.
23. Shwachman, H., Dooley, R. R., Guilmette, F., Patterson, P. R., Weil, C., and Leubner, H. 1956. Cystic fibrosis of the pancreas with varying degrees of pancreatic insufficiency. Am. J. Dis. Child. 92:347-350.
24. Shwachman, H., Lebenthal, E., and Khaw, K. T. 1975. Recurrent acute pancreatitis in patients with cystic fibrosis with normal pancreatic enzymes. Pediatrics 55:86-95.
25. Sifton, D. W., ed. 1994. Physicians Desk Reference. Montvale, NJ: Medical Economics.
26. Smyth, R. L., van Velzen, D., Smyth, A. R., Lloyd, D. A., and Heaf, D. P. 1994. Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes. Lancet 343:85-86.
27. Smyth, R. L., Ashby, D., O'Hea, U., Burrows, E., Lewis, P., van Velzen, D., and Dodge, J. A. 1995. Fibrosing colonopathy in cystic fibrosis: Results of a case-control study. Lancet 346:1247-1251.
28. Stead, R. J., Skypala, I., Hodson, M. E., and Batten, J. C. 1987. Enteric coated microspheres of pancreatin in the treatment of cystic fibrosis: Comparison with a standard enteric coated preparation. Thorax 42:533-537.
29. Taylor, C. J. 1994. The problems with high dose pancreatic enzyme preparations. Drug Safety 11:75-79.
30. Taylor, C. J., and Dodge, J. A. 1994. High strength pancreatic enzyme supplements and large bowel stricture in cystic fibrosis. Lancet 343:110.
31. Valerio, D., Whyte, E. H., Schlamm, H. T., Ruggiero, J. A., and Blackburn, G. L. 1981. Clinical effectiveness of pancreatic enzyme supplement. J. Parenter. Enter. Nutr. 5:110-114.
32. van Velzen, D., Ball, L. M., Dezfulian, A. R., Southgate, A., and Howard, C. V. 1996. Comparative and experimental pathology of fibrosing colonopathy. Post. Med. J. 72(suppl. 2):S39-S48.
33. Wenda, K., Scheurman, H., Weitzel, E., and Rudigler, J. 1988. Pharmacokinetics and methylmethacrylate monomer during total hip replacement in man. Arch. Orthop. Traum. Surg. 107:316-321.